Trial intelligence / Profile preview

AFTER preoperative endocrine exposure study in hormone receptor-positive breast cancer

2008-000644-13Phase 2Active

Sponsor: Netherlands Cancer Institute
Start: Mar 2008
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
Countries: 1

Overview

Phase 2, randomised, open-label trial in breast cancer comparing Anastrozole, Tamoxifen and Anastrozole + fulvestrant (3 arms). Primary endpoints: Change in tumor cell proliferation, Induced apoptosis and 4 more. Started Mar 2008; status: active.

Drugs

anastrozoletamoxifenfulvestrant

Conditions

breast cancer

Beyond the preview

Go deeper on 2008-000644-13.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-000644-13.